Tinea Pedis Clinical Trial
Official title:
A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Cream to Ciclopirox Cream 0.77% in the Treatment of Tinea Pedis
NCT number | NCT00802672 |
Other study ID # | CPL-302 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | December 2003 |
Est. completion date | May 2004 |
Verified date | October 2021 |
Source | Padagis LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objectives of this study were to demonstrate comparable safety and efficacy of Ciclopirox Olamine Cream (Test Product) and Ciclopirox Cream 0.77% (Reference Product) in the treatment of subjects with tinea pedis, and to show the superiority of the active treatments over that of the vehicle.
Status | Completed |
Enrollment | 561 |
Est. completion date | May 2004 |
Est. primary completion date | May 2004 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years and older |
Eligibility | Inclusion Criteria: - Male or female at least 10 years of age, and otherwise healthy - Clinically and mycologically confirmed diagnosis of symptomatic tinea pedis - In good health with no clinically significant disease that might have interfered with study evaluations - Study participant or legal guardian was willing and able to read and sign an IRB approved ICF, which included agreement to comply with all study requirements as indicated in the protocol. For subjects 10 to 17 years of age, an assent form for minors was completed. Exclusion Criteria: - History of hypersensitivity or allergy to ciclopirox - Had any skin condition that would interfere with the diagnosis or assessment of tinea pedis - Had a history of dermatophyte infecton unresponsive to antifungal treatment - Had a history of alcoholism, drug abuse, or problems that would likely have made the subject unreliable for the study - Had any condition or used any medication that, in the opinion of the Investigator, might have interfered with the conduct or results of the study or placed the prospective subject at increased risk - Was unwilling to sign the informed consent - Female who was pregnant or lactating |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Padagis LLC |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Subjects in Each Treatment Group With Therapeutic Success | Both Mycological Cure (KOH wet mount negative and fungal culture negative) and Clinical Cure were required to achieve Therapeutic Success | 6 weeks | |
Secondary | Proportion of Subjects With Mycological Cure | Mycological Cure (KOH wet mount negative and fungal culture negative | 6 weeks | |
Secondary | Proportion of Subjects With Clinical Cure | Clinical Cure was defined as a signs and symptoms score of <1 for erythema; <1 for scaling; and 0 for pruritus, maceration, fissuring/cracking, and burning/stinging; as well as an assessment that no additional antifungal therapy was required to treat the subject's current episode of tinea pedis | 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05493488 -
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis
|
Phase 2 | |
Completed |
NCT04883593 -
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
|
Early Phase 1 | |
Terminated |
NCT02842021 -
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
|
Phase 2 | |
Completed |
NCT01712360 -
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
|
Phase 4 | |
Completed |
NCT00781664 -
Cumulative Irritation Test
|
Phase 1 | |
Completed |
NCT03676686 -
Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis
|
N/A | |
Completed |
NCT01519752 -
A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
|
Phase 1 | |
Completed |
NCT03320486 -
Non-inferiority Trial of Dapaconazole Versus Ketoconazole
|
Phase 3 | |
Completed |
NCT01580891 -
Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis
|
Phase 1 | |
Completed |
NCT01349998 -
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
|
Phase 3 | |
Completed |
NCT01353976 -
Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis
|
Phase 3 | |
Completed |
NCT04265521 -
Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet
|
N/A | |
Completed |
NCT02633813 -
BE Study of Naftifine HCL
|
Phase 3 | |
Recruiting |
NCT00856596 -
Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females
|
Phase 3 | |
Completed |
NCT00869336 -
Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)
|
Phase 2 | |
Completed |
NCT00768599 -
A Study of Econazole Foam 1% in Athlete's Foot
|
Phase 2 | |
Recruiting |
NCT00233493 -
Spread of Dermatophytes Among Families
|
N/A | |
Completed |
NCT03897257 -
A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis
|
Phase 2 | |
Completed |
NCT03129321 -
Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis
|
Phase 3 | |
Completed |
NCT02335255 -
Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis
|
Phase 1 |